United States - English - NLM (National Library of Medicine)

liberty pharmaceuticals, inc. - meloxicam (unii: vg2qf83cgl) (meloxicam - unii:vg2qf83cgl) - meloxicam 7.5 mg - meloxicam tablets are indicated for relief of the signs and symptoms of osteoarthritis [see clinical studies (14.1) ]. meloxicam tablets are indicated for relief of the signs and symptoms of rheumatoid arthritis [see clinical studies (14.1) ]. meloxicam tablets are indicated for relief of the signs and symptoms of pauciarticular or polyarticular course juvenile rheumatoid arthritis in patients 2 years of age and older [see clinical studies (14.2) ]. meloxicam tablets are contraindicated in patients with known hypersensitivity (e.g. anaphylactoid reactions and serious skin reactions) to meloxicam. meloxicam tablets should not be given to patients who have experienced asthma, urticaria, or allergic-type reactions after taking aspirin or other nsaids. severe, rarely fatal, anaphylactic-like reactions to nsaids have been reported in such patients [see warnings and precautions (5.7, 5.13) ]. meloxicam tablets are contraindicated for the treatment of peri-operative pain in the setting of coronary artery bypass

United States - English - NLM (National Library of Medicine)

sterling knight pharmaceuticals, llc - meloxicam (unii: vg2qf83cgl) (meloxicam - unii:vg2qf83cgl) - meloxicam 7.5 mg - meloxicam tablets, usp is indicated for relief of the signs and symptoms of osteoarthritis [ see clinical studies ( 14.1) ]. meloxicam tablets, usp is indicated for relief of the signs and symptoms of rheumatoid arthritis [ see clinical studies ( 14.1) ]. meloxicam tablets, usp is indicated for relief of the signs and symptoms of pauciarticular or polyarticular course juvenile rheumatoid arthritis in patients 2 years of age and older [ see clinical studies ( 14.2) ]. meloxicam is contraindicated in patients with known hypersensitivity (e.g., anaphylactoid reactions and serious skin reactions) to meloxicam. meloxicam should not be given to patients who have experienced asthma, urticaria, or allergic-type reactions after taking aspirin or other nsaids. severe, rarely fatal, anaphylactic-like reactions to nsaids have been reported in such patients [ see warnings

Australia - English - Department of Health (Therapeutic Goods Administration)

apotex pty ltd - meloxicam -

Australia - English - Department of Health (Therapeutic Goods Administration)

apotex pty ltd - meloxicam -

Australia - English - Department of Health (Therapeutic Goods Administration)

helix pharmaceuticals pty ltd - meloxicam, quantity: 7.5 mg - tablet, uncoated - excipient ingredients: lactose monohydrate; povidone; magnesium stearate; sodium citrate dihydrate; colloidal anhydrous silica; crospovidone; microcrystalline cellulose - meloxicam is indicated for symptomatic treatment of osteoarthritis and rheumatoid arthritis.

Australia - English - Department of Health (Therapeutic Goods Administration)

helix pharmaceuticals pty ltd - meloxicam, quantity: 15 mg - tablet, uncoated - excipient ingredients: lactose monohydrate; microcrystalline cellulose; magnesium stearate; colloidal anhydrous silica; sodium citrate dihydrate; povidone; crospovidone - meloxicam is indicated for symptomatic treatment of osteoarthritis and rheumatoid arthritis.

United States - English - NLM (National Library of Medicine)

stat rx usa llc - meloxicam (unii: vg2qf83cgl) (meloxicam - unii:vg2qf83cgl) - meloxicam 7.5 mg - carefully consider the potential benefits and risks of meloxicam tablets and other treatment options before deciding to use meloxicam tablets. use the lowest effective dose for the shortest duration consistent with individual patient treatment goals (see warnings). meloxicam tablets are indicated for relief of the signs and symptoms of osteoarthritis and rheumatoid arthritis. meloxicam tablet is contraindicated in patients with known hypersensitivity to meloxicam. meloxicam tablets should not be given to patients who have experienced asthma, urticaria, or allergic-type reactions after taking aspirin or other nsaids. severe, rarely fatal, anaphylactic-like reactions to nsaids have been reported in such patients (see warnings, anaphylactoid reactions, and precautions, pre-existing asthma). meloxicam tablet is contraindicated for the treatment of peri-operative pain in the setting of coronary artery bypass graft (cabg) surgery (see warnings).

Australia - English - Department of Health (Therapeutic Goods Administration)

amneal pharma australia pty ltd - meloxicam -

Australia - English - Department of Health (Therapeutic Goods Administration)

amneal pharma australia pty ltd - meloxicam -

United States - English - NLM (National Library of Medicine)

readymeds - meloxicam (unii: vg2qf83cgl) (meloxicam - unii:vg2qf83cgl) - meloxicam 7.5 mg - meloxicam is indicated for relief of the signs and symptoms of osteoarthritis [see clinical studies (14.1) ]. meloxicam is indicated for relief of the signs and symptoms of rheumatoid arthritis [see clinical studies (14.1) ]. meloxicam is contraindicated in patients with known hypersensitivity (e.g., anaphylactoid reactions and serious skin reactions) to meloxicam. meloxicam should not be given to patients who have experienced asthma, urticaria, or allergic-type reactions after taking aspirin or other nsaids. severe, rarely fatal, anaphylactic-like reactions to nsaids have been reported in such patients [see warnings and precautions (5.7, 5.13) ]. meloxicam is contraindicated for the treatment of peri-operative pain in the setting of coronary artery bypass graft (cabg) surgery [see warnings and precautions (5.1) ]. pregnancy category c; category d starting 30 weeks gestation there are no adequate and well-controlled studies in pregnant women. meloxicam crosses the placental barrier. prior to 30 weeks gestatio